Monitor progress of the Phase 3 trial for BIV201 and watch for additional capital raises, as the IPO proceeds may not be sufficient to complete the trial. The company's dependence on BioVie for management and services creates operational risk.
Executive Summary
Option Therapeutics Inc. (OPTN) is conducting an IPO to fund a Phase 3 clinical trial for BIV201, a continuous infusion terlipressin therapy for patients with cirrhosis and ascites. The company, currently a wholly-owned subsidiary of BioVie, will retain BioVie as a majority shareholder (64%) post-offering. The $17 million net proceeds will fund the pivotal trial, but the company faces significant risks including lack of revenue, dependence on BioVie for management services, and substantial future capital needs.
Key Financial Metrics
Key Facts
- Company is a clinical-stage biotech developing BIV201 for liver cirrhosis complications (ascites, AKI)
- IPO raises $17M net proceeds (up to $19.7M with over-allotment) at $10-12/share for 1.8M shares
- BioVie will retain 64% ownership post-IPO, maintaining control and providing management services
- Proceeds will fund Phase 3 trial of BIV201, which has Fast Track and Orphan Drug designations
- Company reported net losses of $1.2M (2025) and $451k (6mo 2025) with no revenue
- Significant risks include dependence on BioVie, future capital needs, and clinical trial uncertainties
Financial Impact
Raises $17-19.7 million in net proceeds to fund Phase 3 trial; company remains unprofitable with $1.2M net loss in FY2025
Risk Factors
- Company has no revenue and significant operating losses
- Dependence on BioVie for management services and majority control
- IPO proceeds may not be sufficient to complete Phase 3 trial
- Clinical trial results are uncertain and regulatory approval not guaranteed
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001520138-26-000074 |
| Document: opti-202603_s1a1ex10z1.htm | 0001520138-26-000074 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers